The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

We have extended our partnership with BeOne Medicines and BeOne Care Foundation to provide access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively by the end of 2028. Read the full press release.

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • Spot On CML Grows in the Philippines

    Spot On CML Grows in the Philippines

    Today, Spot On CML is active in 19 countries and, on June 29th, 17 patients were chosen by the treating physicians at Philippine General Hospital to take part in the program. While CML testing is available in the Philippines, it’s prohibitively expensive – placing critical diagnostic information out of reach for many patients.

  • Join us at the American Society of Hematology (ASH)

    Join us at the American Society of Hematology (ASH)

    Traveling to the American Society of Hematology’s (ASH) annual meeting on December 7–10? We hope to see you at one of our sessions! Save these events to your calendar: The Max Foundation and iCMLf: Forum for Physicians from Emerging Economic Regions When & Where: Friday, December 6, from 12–2 p.m. at the Rosen Plaza Hotel in Orlando, Florida. Each year, ASH joins thousands of leaders around the world….

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….